Latest
News and public updates
30 items from public sources: Federal Register and DEA notices, FDA letters and recalls, North Carolina bills, poison-center reports, new studies and news. Each links to the original.
Federal Register and DEA
· Federal Register (DEA)
DEA companion notice published: MGM-15 and MGM-16 stay in Schedule I (opens in a new tab)
Companion notice of intent published Oct 14 so MGM-15 and MGM-16 stay controlled while DEA revises the related 7-OH and MGPI notice. The August 26 temporary order stays in force until a new order replaces it.
· Federal Register (DEA)
DEA notice published: 7-OH and MGPI above a set limit headed for Schedule I (opens in a new tab)
Notice of intent published Oct 14. Covers 7-OH and MGPI when either alone, or both combined, is above 1 mg per gram (solids) or 1 mg per mL (liquids), or when the mitragynine-to-target mass ratio is under 100. The temporary order can publish on or after Nov 13. July notice is…
· U.S. Department of Justice
Justice Department announces updates to emergency scheduling for 7-OH and related substances (opens in a new tab)
DOJ describes DEA's new notices of intent that use HHS's updated concentration and ratio limits for concentrated 7-OH and MGPI products.
· HHS
HHS recommends limits for enhanced kratom products (7-OH and MGPI) (opens in a new tab)
Schedule I if 7-OH, MGPI or both exceed 1 mg per gram or 1 mg per mL, which should cover vape liquids.
· Federal Register (Health and Human Services Department)
Hydroxymitragynine Above a Specified Threshold in Schedule I; Extension of Comment Period (opens in a new tab)
The Office of the Assistant Secretary for Health (OASH or we) is extending the comment period to solicit input and comments on a Request for Information (RFI) on a proposed threshold for 7- hydroxymitragynine (7-OH) scheduling under the Controlled Substances Act that appeared…
· Federal Register (Justice Department, Drug Enforcement Administration)
Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (opens in a new tab)
The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenev…
· Federal Register (Justice Department, Drug Enforcement Administration)
Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I (opens in a new tab)
The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule 7-hydroxymitragynine above a specified threshold, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever…
· Federal Register (Justice Department, Drug Enforcement Administration)
Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (opens in a new tab)
The Administrator of the Drug Enforcement Administration is issuing this notice of intent to publish a temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and…
· Federal Register (Health and Human Services Department)
Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Request for Information (opens in a new tab)
The Office of the Assistant Secretary for Health (OASH or we) is opening a public docket to solicit input and comments on a proposed threshold for 7-hydroxymitragynine (7-OH) scheduling under the Controlled Substances Act. Public comments submitted to this docket will be provi…
NC legislature
· NC General Assembly
House Bill 328: conference report sent to House Rules committee (opens in a new tab)
The Senate adopted the conference report 37-6 on July 2. The House could take it up Oct 26-28, Nov 16-19 or Nov 30 - Dec 18.
· NC General Assembly
Senate Bill 59 (hemp products and kratom): House committee approves a new version and sends it to House Rules (opens in a new tab)
The Senate passed this bill 44-0 in March 2025. On June 10, 2026 a House committee approved a rewritten version, and it now waits in the House Rules committee alongside HB 328.
Poison center and CDC
· Michigan Poison & Drug Information Center
Michigan poison center explains the risks of concentrated 7-OH products (opens in a new tab)
Michigan's poison center saw kratom exposures rise in 2025, including 69 involving children, and says 7-OH-enhanced products brought more overdoses, harder withdrawal and more ICU stays; the state health department now urges doctors to ask patients about these products.
· America's Poison Centers
Poison centers: 901 concentrated 7-OH exposures in the first half of 2026, up from 593 in all of 2025 (opens in a new tab)
About 39% of 7-OH-only exposures had serious outcomes and about 1 in 5 people were hospitalized.
· CDC MMWR
CDC MMWR: kratom poison-center reports rose about 1,200% from 2015 to 2025 (opens in a new tab)
U.S. poison centers logged 14,449 kratom-related reports from 2015–2025 in a CDC MMWR analysis, peaking at 3,434 in 2025 (up from 258 in 2015; ages 12+). America's Poison Centers reported 3,803 kratom-or-derivative exposures in 2025 and 3,190 in Jan–Jun 2026 — higher than MMWR…
FDA letters and recalls
· FDA
FDA page: concentrated 7-OH products and the new HHS threshold approach (opens in a new tab)
FDA explains the Oct 9 notices of intent and the 1 mg per gram or per mL (or ratio under 100 to 1) approach meant to target enhanced products.
· FDA enforcement report
Ongoing FDA enforcement listing: White Vein Advanced Alkaloids chewables (7-OH) (opens in a new tab)
Class I listing for a 7-OH chewable where the active amount was higher than labeled. Status listed as ongoing.
· FDA
Recall: Shaman Botanicals White Vein chewables (7-OH above labeled amount) (opens in a new tab)
Company recalled one lot after testing found more 7-OH than the label claimed. Sold nationwide.
· US Department of Justice and FDA
Federal seizure of about 73,000 concentrated 7-OH units from three Missouri warehouses (opens in a new tab)
About $1 million in products taken off the market.
· FDA enforcement report
Recall: Monarch Premium Kratom powders (possible Salmonella) (opens in a new tab)
Lotus Vaping Technologies recalled four kratom powders.
· FDA
FDA warning letters to seven firms selling concentrated 7-OH products (opens in a new tab)
FDA told seven companies their concentrated 7-OH tablets, gummies, shots and similar products are not lawful dietary supplements or foods.
News
· New York Post
Investigation finds 7-OH sold at most NYC smoke shops checked (opens in a new tab)
7-OH at 34 of 52 shops; MGPI or MGM-15 at 8.
· Tri-State Alert
Pennsylvania House unanimously passes a bill to regulate kratom and ban concentrated 7-OH products (opens in a new tab)
House Bill 2657 would limit sales of natural-leaf kratom to adults 21 and over, require clear labels and child-resistant packaging, and ban products above 0.5% 7-OH. It now goes to the state Senate.
· CBHD News
HB 328 still in House Rules; next windows Oct 26-28, Nov 16-19, and late November (opens in a new tab)
Confirms no House vote yet and that Speaker Hall has said the House would wait until after the November election.
New studies
· PubMed · Drug and Alcohol Dependence
Kratom use and moment-to-moment anxiety and sadness over 15 days (opens in a new tab)
A phone-based diary study of 357 adults found small, short-term drops in self-reported anxiety after kratom use; the authors say longer and controlled studies are still needed.
· PubMed · Hawaii J Health Soc Welf
Managing 7-Hydroxymitragynine Use Disorder with Buprenorphine-Naloxone (opens in a new tab)
· PubMed · Regul Toxicol Pharmacol
Beyond kratom: Concentrated 7-hydroxymitragynine and mitragynine pseudoindoxyl products, an MME potency assessment (opens in a new tab)
· PubMed · Am J Drug Alcohol Abuse
Semi-synthetic kratom derivatives in the Czech online market prior to regulatory reform: a baseline surveillance study (opens in a new tab)
· PubMed · J Med Toxicol
ACMT Position Statement: Public Health Risks of 7-Hydroxymitragynine and Other Kratom-Associated Compounds (opens in a new tab)
· PubMed · J Med Toxicol
Kratom-Associated Pulmonary Toxicity: A Systematic Review of Case Reports and Forensic Series with a Proposed Clinical Phenotype Classification (opens in a new tab)
· PubMed · J Addict Med
Kratom-labeled Products in the US Compared With Traditionally Consumed Natural Kratom in Southeast Asia (opens in a new tab)